文献速递骨质疏松与代谢性骨病创伤骨科

25-羟维生素D水平与骨折风险的关系:基于人群的回顾性队列研究

The relationship of 25-hydroxyvitamin D values and risk of fracture: a population-based retrospective cohort study.
PubMed 文献 · Osteoporos Int · 2020-05-06

该研究利用美国明尼苏达州奥姆斯特德县2005至2011年11002名有25(OH)D检测的成人数据,分析25(OH)D水平与骨折风险的关系。结果显示,与20-50 ng/mL相比,<12、12-19和>50 ng/mL的25(OH)D水平总体上不增加骨折风险;但严重低水平(<12 ng/mL)可能与骨质疏松性骨折(尤其腕部骨折)风险增加相关。

要点

  • 25(OH)D <12、12-19和>50 ng/mL与20-50 ng/mL相比,总体骨折风险无显著差异。
  • 校正既往骨质疏松/骨量减少诊断后,仅<12 ng/mL者骨质疏松性骨折(aHR=1.41)和腕部骨折(aHR=2.11)风险增加。
  • 无既往骨质疏松/骨量减少诊断者中,<12 ng/mL与任何骨折、骨质疏松性骨折和腕部骨折风险增加相关。

核心结论

  • 严重低25(OH)D水平(<12 ng/mL)可能与骨质疏松性骨折风险增加相关,尤其是腕部骨折。
  • 25(OH)D值>50 ng/mL未显示与骨折风险增加相关。

研究设计与样本

  • 基于人群的回顾性队列研究,纳入2005年1月1日至2011年12月31日期间居住于明尼苏达州奥姆斯特德县且至少有一次25(OH)D检测的所有成人患者。
  • 从25(OH)D检测后30天开始检索骨折结局,直至患者作为奥姆斯特德县居民的最后一次临床就诊、2014年12月31日或死亡。
  • 数据分析采用Cox比例风险回归。

主要发现

  • 共11002名有25(OH)D检测的个体,其中5.8%的25(OH)D值<12 ng/mL,5.1%的值>50 ng/mL。
  • 与20-50 ng/mL参考组相比,<12、12-19和>50 ng/mL组总体骨折风险无关联。
  • 校正既往骨质疏松/骨量减少诊断后,仅<12 ng/mL组与参考组相比,任何骨质疏松性骨折风险增加(aHR=1.41;95% CI 1.05-1.89),腕部骨折风险增加(aHR=2.11;95% CI 1.27-3.48)。
  • 在无既往骨质疏松/骨量减少诊断的受试者中,与参考组相比,<12 ng/mL组与任何骨折风险增加相关(aHR=1.35;95% CI 1.01-1.80),骨质疏松性骨折风险增加(aHR=2.18;95% CI 1.44-3.31),腕部骨折风险增加(aHR=2.39;95% CI 1.19-4.81);在有既往诊断的受试者中无此关联。

关键数值与推荐

  • 25(OH)D参考组为20-50 ng/mL。
  • 25(OH)D值<12 ng/mL、12-19 ng/mL和>50 ng/mL与参考组相比,总体骨折风险无显著关联。
  • 校正既往骨质疏松/骨量减少诊断后,<12 ng/mL组任何骨质疏松性骨折aHR=1.41(95% CI 1.05-1.89),腕部骨折aHR=2.11(95% CI 1.27-3.48)。
  • 无既往骨质疏松/骨量减少诊断者中,<12 ng/mL组任何骨折aHR=1.35(95% CI 1.01-1.80),骨质疏松性骨折aHR=2.18(95% CI 1.44-3.31),腕部骨折aHR=2.39(95% CI 1.19-4.81)。

临床怎么用

  • 对于25(OH)D水平严重降低(<12 ng/mL)的患者,尤其无既往骨质疏松/骨量减少诊断者,应关注骨质疏松性骨折(特别是腕部骨折)风险。
  • 25(OH)D值>50 ng/mL未显示增加骨折风险,无需因担心骨折风险而限制该水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Our study investigates 25-hydroxyvitamin D levels and fracture risk using population-level data. 25-Hydroxyvitamin D values < 12, 12-19, and > 50 ng/mL were not associated with increased risk of fractures overall compared with values 20-50 ng/mL. Severely low levels may be associated with increased risk of osteoporotic fracture, particularly of the wrist. INTRODUCTION: Studies of the relationship between serum 25-hydroxyvitamin D (25(OH)D) levels and fracture risk have been inconsistent. We hypothesized that high 25(OH)D concentrations (> 50 ng/mL) would be associated with increased risk of fracture. METHODS: We identified all adult patients living in Olmsted County, Minnesota, between January 1, 2005 and December 31, 2011, who had at least one 25(OH)D measurement. Fracture outcomes were retrieved starting 30 days after 25(OH)D measurement and until patients' final clinical visit as an Olmsted County resident, December 31, 2014, or death. Data were analyzed using Cox proportional hazard regression. RESULTS: Of 11,002 individuals with a 25(OH)D measurement, 5.8% had a 25(OH)D value ˂ 12 ng/mL, and 5.1% had a value > 50 ng/mL. Compared with subjects with 25(OH)D values 20-50 ng/mL (reference group), values < 12, 12-19, and > 50 ng/mL displayed no association with overall fracture risk. After adjusting for a prior diagnosis of osteoporosis/osteopenia, only individuals with values ˂ 12 ng/mL had increased risk of any osteoporotic fracture (aHR = 1.41; 95% CI 1.05-1.89) and wrist fracture (aHR = 2.11; 95% CI 1.27-3.48) compared with the reference group. Compared with the reference group, values ˂ 12 ng/mL were associated with increased risk of any fracture (aHR = 1.35; 95% CI 1.01-1.80), osteoporotic fracture (aHR = 2.18; 95% CI 1.44-3.31), and wrist fracture (aHR = 2.39; 95% CI 1.19-4.81) in subjects without a prior diagnosis of osteoporosis/osteopenia, but not in those with a prior diagnosis of osteoporosis/osteopenia. CONCLUSION: Severely low 25(OH)D levels may be associated with increased risk of osteoporotic fracture, particularly of the wrist, but 25(OH)D values > 50 ng/mL were not associated with increased fracture risk.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Aul AJ, Dudenkov DV, Mara KC, et al. The relationship of 25-hydroxyvitamin D values and risk of fracture: a population-based retrospective cohort study. Osteoporos Int. 2020. PMID: 32377805. doi:10.1007/s00198-020-05436-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。